Background {#Sec1}
==========

Epidemiological studies have confirmed that the presence of diabetes mellitus (DM) is associated with an increased risk of developing heart failure (HF) \[[@CR1], [@CR2]\]. Indeed, HF is often the first cardiovascular manifestation observed in diabetic patients \[[@CR3]\]. The increased risk of HF persists even after adjustment for confounders such as coronary artery disease and hypertension. Further, diabetic patients with HF have a poor prognosis \[[@CR4]\].

It is challenging to stratify risk for patients with HF. Established risk factors such as left ventricular ejection fraction (LVEF), New York Heart Association (NYHA) functional class, comorbidities (DM, anemia, and renal insufficiency), and treatment strategies do not fully explain the mortality risk associated with HF patients \[[@CR5]--[@CR7]\]. Prognostication may be refined by measurement of biomarkers for different pathophysiological processes not reflected by established mortality risk factors \[[@CR8]\] Circulating biomarkers measured in patients with HF are classified into seven pathophysiological pathways, including myocardial stretch, myocyte injury, extracellular matrix, inflammation, renal dysfunction, neurohormonal activation, and oxidative stress \[[@CR9], [@CR10]\]. In recent years, there is a growing interest in relation to the clinical usefulness of these biomarkers in patients with diabetes \[[@CR11]\] as well as to their pathogenic role in the development of vasculopathy \[[@CR12], [@CR13]\]. Some of these biomarkers have been shown to be associated with the risk of diabetes \[[@CR14]--[@CR16]\] and their serum levels were described to be modified by medical treatment \[[@CR17]\]. It is unclear whether systemic diseases such as DM may affect the predictive value of these HF biomarkers. Accordingly, our aim in the present study was to assess whether DM had any impact on the predictive value of a multi-biomarker panel in patients with HF. We included the following biomarkers: N-terminal pro-brain natriuretic peptide (NT-proBNP; myocardial stretch and neurohormonal activation), neprilysin (neurohormonal activation), galectin-3 (extracellular matrix), ST2 (inflammation, stretch, and extracellular matrix), high-sensitivity troponin T (hs-TnT; myocardial injury), cystatin-C (renal dysfunction), high-sensitivity C reactive protein (hs-CRP; inflammation), and soluble transferrin receptor (sTfR; oxidative stress).

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

The present study is a subanalysis of a previous investigation of the performance of different biomarkers in a well-established HF cohort \[[@CR10]--[@CR13]\]. From May 2006 to 2013, ambulatory patients treated at a multidisciplinary HF clinic were consecutively included in the study. Referral inclusion criteria and blood sample collection are described elsewhere \[[@CR4]--[@CR7]\]. All analyses of biomarkers were performed on the same blood sample, which had been stored at −80° without prior freeze--thaw cycles. All samples were obtained between 9:00 a.m. and 12:00 p.m. Serum concentrations of NT-proBNP (*N* = 1030), hs-TnT (*N* = 803), ST2 (*N* = 814), galectin-3 (*N* = 811), hs-CRP (*N* = 773 after we excluded 16 patients with levels ≥100 mg/dL), cystatin-C (*N* = 804), STfR (*N* = 794), and neprilysin (*N* = 1069) were measured.

All of the participants provided written informed consent, and the local ethics committee approved the study. All of the study procedures were in accordance with the ethical standards outlined in the Helsinki Declaration of 1975 (revised in 1983).

Follow-up and outcomes {#Sec4}
----------------------

All patients made follow-up visits at regular, predefined intervals, and they made additional visits as required in cases of decompensation. The regular visitation schedule included a minimum of quarterly visits with nurses; biannual visits with physicians; and elective visits with geriatricians, psychiatrists, and rehabilitation physicians. Patients who did not attend the regular visits were contacted by telephone.

The primary outcomes of the present study were all-cause and cardiovascular death. A death was considered cardiovascular in origin if it was caused by HF (decompensated HF or treatment-resistant HF in the absence of another cause), sudden death (unexpected death, witnessed or not, of a previously stable patient with no evidence of worsening HF or any other cause of death), acute myocardial infarction (due to mechanical, haemodynamic, or arrhythmic complications), stroke (in association with recent acute neurological deficits), procedural (death after diagnostic or therapeutic procedures), and other cardiovascular causes (e.g., rupture of an aneurysm, peripheral ischaemia, or aortic dissection). Fatal events were identified from paper and electronic clinical records, from general practitioners, and by contacting the patients' relatives. Data were verified by comparisons with the databases of the Catalan and Spanish health systems. Events were adjudicated by two of the authors (MD and JL). Follow-up was closed on 30 September 2015. Five patients were lost during follow-up and appropriately censored.

DM diagnosis {#Sec5}
------------

A diagnosis of DM was made when one of the following criteria were met: (1) a diagnosis of DM was previously established and recorded in the patient's electronic history, (2) fasting plasma glucose ≥126 mg/dL or HbA1c ≥6.5% identified by laboratory testing \[[@CR18]\], or (3) the patient had a current prescription for oral hypoglycaemic medication or insulin. All the included patients in this study had type 2 diabetes.

NTproBNP assay {#Sec6}
--------------

NTproBNP levels were determined by an immunoelectrochemiluminescence method (Elecsys®; Roche Diagnostics, Switzerland). The assay had inter-run CVs of 0.9--5.5%.

Hs-TnT assay {#Sec7}
------------

Hs-TnT levels were measured by electrochemiluminescence immunoassay on the Modular Analytics E 170 (Roche Diagnostics). The hs-TnT assay had an analytic range of 3--10,000 ng/L. At the 99th percentile value of 13 ng/L, the CV was 9%.

ST2 assay {#Sec8}
---------

ST2 levels were measured from plasma samples with a high-sensitivity sandwich monoclonal immunoassay (Presage® ST2 assay; Critical Diagnostics, San Diego, CA, USA). The ST2 assay had a within-run coefficient of \<2.5% and total CV of 4%.

hsCRP assay {#Sec9}
-----------

hsCRP concentrations were measured by particle-enhanced turbidimetry (CRPHS, ref. 04628918 190; Roche Diagnostics) on the automatic analyser Cobas 6000 (Roche Diagnostics). The linearity of the method was 0.15--20.0 mg/L, the detection limit was 0.15 mg/L, the functional sensitivity was 0.3 mg/L, and the interserial CV was \<8.4%.

Galectin-3 assay {#Sec10}
----------------

For galectin-3 measurements, we used an enzyme-linked fluorescent assay (BioMerieux ref. 411191) on a mini-VIDAS® analyser (BioMerieux, France). The CV for the assay was \<10%, the linearity was 3.3--100.0 ng/mL, and the limit of detection was 2.4 ng/mL.

Cystatin-C assay {#Sec11}
----------------

Cystatin C was measured by a nephelometric technique that assesses immune complex formation between cystatin and antiserum anticystatin-C attached to latex particles (Cystatin C Radim, ref. NPP42; Radim Group, Pomezia, Italy). The CV between assays was 2.9%.

STfR assay {#Sec12}
----------

Soluble transferrin receptor concentrations were measured with a particle-enhanced turbidimetric immunoassay (Tina-quant Soluble Receptor Transferrin STFR, Roche Diagnostics) on the automatic analyser Cobas 6000 (Roche Diagnostics). The linearity of the method was 0.5--40.0 mg/L, the detection limit was 0.50 mg/L, and the interserial CV was \<3.8%.

Neprilysin assay {#Sec13}
----------------

Human neprilysin (NEP) was measured with a modified sandwich immunoassay (HUMAN NEP/CD10 ELISA kit, ref. SK00724-01, lot no. 20111893; Aviscera Biosciences, Santa Clara, CA, USA). At a positive control value of 1.4 ng/mL, the intra- and interassay CVs were 3.7 and 8.9%, respectively.

Statistical analysis {#Sec14}
--------------------

Categorical variables are expressed as percentages. Continuous variables are expressed as means (SD) or medians (quartiles Q1--Q3) for normal and non-normal distributions, respectively. Normal distribution was assessed with normal Q--Q plots. Differences between nondiabetic and diabetic patients were assessed by Chi-squared test, Student's *t* test, and Mann--Whitney U test, as required. We also assessed differences in the levels of the different biomarkers between nondiabetic and diabetic patients (subsequent to log transformation) after adjustments for age, sex, body mass index, and estimated glomerular filtration rate.

We performed two Cox regression analyses, with all-cause or cardiovascular death as the dependent variable and the selected biomarker plus DM plus the interaction between the covariate biomarker and DM as independent covariables. In the Cox models, to fulfill the assumption of linearity of the covariables NT-proBNP, hs-TnT, ST2, hs-CRP, galectin-3, and sNEP, we used the logarithmic functions of NT-proBNP, hs-TnT, hs-CRP, galectin-3, and sNEP; the quadratic term of ST2; and log(hs-TnT). Afterwards, Cox regression analyses were performed separately for diabetic and nondiabetic patients for each biomarker. We used a 1SD increase, calculated jointly for the whole cohort, for HR calculations in the five logarithm-transformed variables. ST2 analyses were performed for every 10 ng/mL change. In patients with sNEP levels below the lower range of detection (0.250 ng/mL), a concentration of 0.249 ng/mL was introduced as a continuous variable. Survival curves for all-cause death were plotted for nondiabetic and diabetic patients based on the best cut-off points of ST2, obtained from AUC. As a sensitivity analysis of the 265 diabetic patients with all the biomarkers collected, we performed two comprehensive multivariable Cox regression analyses with all the biomarkers and also clinical variables, again for all-cause and cardiovascular death. Finally, a simple clinical model (age, sex, New York Association functional class, left ventricular ejection fraction and estimated glomerular filtration rate (CKD-EPI equation) was developed and discrimination evaluated (AUC) adding each one of the biomarkers and the best short combinations. Statistical analyses were performed with SPSS 15 (SPSS Inc., Chicago, IL, USA) and version 2.11.1 of the R statistical package (Foundation for Statistical Computing, Vienna, Austria). Two-sided *p* \< 0.05 was considered significant.

Results {#Sec15}
=======

We included 1069 consecutive ambulatory HF patients in the study. Table [1](#Tab1){ref-type="table"} lists the clinical characteristics of the total cohort and statistical differences based on the presence or absence of DM. The mean age was 66.2 ± 12.8 years, and 72% of the patients were men. The predominant HF etiology was ischaemic heart disease (51%), and the mean LVEF was 33.5 ± 13.3%. In total, 385 patients (36%) had DM. Upon inclusion, 198 and 151 patients were receiving oral antidiabetic medication and insulin, respectively; 39 patients were taking both. During follow-up, these numbers increased to 285 and 241, respectively (166 patients were receiving both treatments). As expected, many of the clinical characteristics were different between nondiabetic and diabetic patients (Table [1](#Tab1){ref-type="table"}). For example, serum concentrations of five of the eight studied biomarkers were higher in diabetic patients: NTproBNP (*p* = 0.07), hs-TnT (*p* \< 0.001), galectin-3 (*p* \< 0.001), cystatin-C (*p* = 0.001), and sTfR (*p* = 0.005) (Table [1](#Tab1){ref-type="table"}). After adjustment for age, sex, body mass index, and estimated glomerular filtration rate, NTproBNP (*p* = 0.01), hs-TnT (*p* \< 0.001), and sTfR (*p* \< 0.05) levels remained significantly higher in diabetic patients, while levels of galectin-3 (*p* = 0.1), cystatin-C (*p* = 0.86), hs-CRP (*p* = 0.62), sNEP (*p* = 0.61), and ST2 (*p* = 0.28) were no longer significantly different between the two groups.Table 1Clinical characteristics and treatment during follow-up categorised according to diabetic statusCharacteristicsNondiabetic\
*N* = 684DM\
*N* = 385*p* valueAge, years65.3 ± 1467.8 ± 10.30.002Men501 (73.2)267 (69.4)0.17White677 (99)384 (99.7)0.18Aetiology\<0.001 Ischaemic heart failure310 (45.3)235 (61)\<0.001 Dilated cardiomyopathy80 (11.7)43 (11.2)0.94 Hypertensive60 (8.8)37 (9.6)0.50 Valvular81 (11.8)36 (9.4)0.15 Alcohol48 (7)10 (2.6)0.001 Other105 (15.3)24 (6.2)0.01HF duration, months24 (3--70.8)24 (4--71.6)0.77LVEF, %33.7 ± 13.333.1 ± 13.20.61NYHA class III--IV154 (22.5)107 (27.8)0.54Hypertension392 (44.2)286 (74.3)\<0.001Peripheral arteriopathy75 (11)82 (21.3)\<0.001COPD125 (18.3)56 (14.5)0.12BMI, Kg/m^2^26.4 (23.9--29.7)27.6 (25--31.2)\<0.001Heart rate, bpm71.4 ± 14.673 ± 13.50.07Blood pressure, mmHg125.8 ± 22.2128.8 ± 23.40.04eGFR, mL/min/1.73 m^2^57.7 ± 27.250.9 ± 24.9\<0.001Sodium, mmol/L139.2 ± 3.4137.9 ± 8.4\<0.001Haemoglobin, g/dL13.1 ± 1.912.5 ± 1.8\<0.001Biomarkers NTproBNP, ng/L1183 (494--2679)1469 (629--3697)0.007 hs-TnT, ng/L19.1 (9.1--36.4)28.6 (14.7--44.6)\<0.001 ST2, ng/mL38 (30.3--49.9)38.6 (31.3--52.6)0.23 hs-CRP, mg/L3.2 (1.3--8.3)4.2 (1.4--8.7)0.28 Galectin-3, ng/mL15.6 (11.8--21.5)17.4 (14--23.4)\<0.001 Cystatin-C, mg/L1.28 (1.04.--1.73)1.42 (1.13--1.89)0.001 Neprilysin, ng/mL0.63 (0.38--1.23)0.66 (0.39--1.09)0.71 STfR, mg/L3.6 (2.8--4.6)3.9 (3--4.9)0.005Treatments, *N* (%) ACEI or ARB617 (90.2)335 (87.0)0.11 Beta-blocker611 (89.3)353 (91.7)0.21 MRA378 (55.3)245 (63.6)0.008 Loop diuretic605 (88.5)365 (94.8)0.001 Digoxin262 (38.3)151 (39.2)0.77 CRT55 (8)32 (8.3)0.88 ICD90 (13.2)50 (13)0.94Data presented as mean ± SD, median (interquartile range), or *N* (%)*ACEI* angiotensin converting enzyme inhibitor, *ARB* angiotensin II receptor blocker, *BMI* body mass index, *COPD* chronic obstructive pulmonary disease, *CRT* cardiac resynchronisation therapy, *DM* diabetes mellitus, *eGFR* estimated glomerular filtration rate (CKD-EPI equation), *HF* heart failure, *hs*-*CRP* high-sensitivity C reactive protein, *hs*-*TnT* high-sensitivity troponin T, *ICD* implantable cardiac defibrillator, *LVEF* left ventricular ejection fraction, MRA mineralcorticoid receptor antagonists, *NYHA* New York Heart Association, *NTproBNP* N-terminal pro-brain natriuretic peptide, *STfR* soluble transferrin receptor

During a mean follow-up period of 4.9 ± 2.8 years (6.6 ± 2.3 years for patients who did not die in the follow-up period), 534 patients died. Of the patients who died, 284 died from cardiovascular causes: 137 of progressive HF, 67 of sudden death, 26 of acute myocardial infarction, four of stroke, six during cardiovascular procedures, and 31 of other cardiovascular causes. One hundred and ninety-six patients died of noncardiovascular causes, while the cause of death was unknown in 54 patients. As expected, both all-cause and cardiovascular mortality were higher in diabetic patients (57.7 vs. 45.6%, *p* \< 0.001 and 34.8 vs. 24.2%, respectively; *p* \< 0.001).

There were no interactions between the majority of the biomarkers and DM with respect to prediction of risk of all-cause or cardiovascular death (Fig. [1](#Fig1){ref-type="fig"}). However, ST2 significantly interacted with DM for all-cause (*p* = 0.02) and cardiovascular (*p* = 0.03) death.Fig. 1HRs and 95% CIs for biomarkers based on the presence or absence of DM, and statistical significance of the interaction covariate for DM and the biomarkers. A 1SD increase was used for HR calculations in the logarithm-transformed variables NTproBNP, hs-TnT, hs-CRP, cystatin-C, galectin-3, STfR, and neprilysin. ST2 analyses were performed for every 10 ng/mL change. Age was included as a covariate in the neprilysin analysis. For the quadratic form of ST2: *p* = 0.02 for all-cause death and *p* = 0.03 for cardiovascular death. For the quadratic form of log(hs-TnT): *p* = 0.82 for all-cause death and *p* = 0.1 for cardiovascular death. Interactions between DM and the quadratic form of ST2: *p* = 0.02 for all-cause death and *p* = 0.03 for cardiovascular death. Interactions between DM and the quadratic form of log(hs-TnT): *p* = 0.82 for all-cause death and *p* = 0.1 for cardiovascular death. hs-CRP, high-sensitivity C reactive protein; hs-TnT, high-sensitivity troponin T; NTproBNP, N-terminal pro-brain natriuretic peptide; STfR, soluble transferrin receptor

Figure [1](#Fig1){ref-type="fig"} shows the HRs and 95% CIs of Cox regression analyses for each biomarker for nondiabetic and diabetic patients, both for all-cause (left) and cardiovascular (right) death. In diabetic patients, the HRs for ST2 were 1.27 (95% CI 1.16--1.40, *p* \< 0.001) and 1.23 (95% CI 1.09--1.39, *p* = 0.001) for all-cause and cardiovascular death, respectively. In nondiabetic patients, the HRs for ST2 were 1.53 (95% CI 1.35--1.73, *p* \< 0.001) and 1.64 (95% CI 1.31--2.05, *p* \< 0.001) for all-cause and cardiovascular death, respectively. Survival curves for diabetic and nondiabetic patients based on the best cut-off of ST2 values are shown in Fig. [2](#Fig2){ref-type="fig"}. Divergence of the curves and HRs are also mildly higher in nondiabetic than in diabetic patients. Table [2](#Tab2){ref-type="table"} shows, in a sensitivity analysis, multivariable Cox regression analyses performed in the 265 diabetic patients with all the biomarker studied. Hs-TnT, ST2 and cystatin-C remained statistically associated with all-cause death and hs-TnT, ST2 and galectin-3 with cardiovascular mortality. Finally, Discrimination analysis using a simple clinical model and the studied biomarkers and the best short combinations of them, according also to the previous multivariable analysis are shown in Table [3](#Tab3){ref-type="table"}. Results show that the combination of two biomarker such as hs-TnT and ST2 significantly improved discrimination, as assessed by confidence intervals.Fig. 2Cox regression survival curves for all-cause mortality relative to the best cut-off point of ST2. **a** Nondiabetic patients; **b** diabetic patients Table 2Multivariable Cox regression analyses for risk of all-cause and cardiovascular death in diabetic patientsAll-cause deathCardiovascular deathHR95% CI*p* valueHR95% CI*p* valueAge1.041.02--1.06\<0.0011.021.00--1.050.04Female sex0.770.54--1.110.160.700.43--1.130.15Ischemic etiology of HF0.900.64--1.270.560.980.63--1.520.92LVEF1.011.00--1.030.021.021.00--1.030.03NYHA functional class1.831.37--2.44\<0.0011.751.18--2.580.005eGFR1.000.99--1.020.551.000.99--1.010.69Hemoglobin1.020.96--1.130.721.010.89--1.150.85ACEI or ARB treatment0.780.47--1.280.320.760.39--1.490.42β-blocker treatment0.930.52--1.650.791.060.49--2.300.89NT-proBNP^a^1.150.93--1.430.211.240.93--1.650.15Hs-TnT^a^1.321.08--1.630.0081.531.13--2.050.005ST2^b^1.201.09--1.33\<0.0011.181.03--1.340.01Neprilysin^a^0.990.85--1.160.910.990.80--1.220.94Galectin-3^a^1.120.92--1.370.251.271.03--1.570.02Cystatin-C^a^1.311.11--1.540.0011.220.82--1.820.32Hs-CRP^a^0.910.78--1.060.241.050.85--1.290.65STfR^a^1.060.88--1.280.541.060.83--1.340.65All *p* values are those found in the last step remaining in the model. *p* value for (ST2)^2^: All-cause mortality, p = 0.005; Cardiovascular mortality, p = 0.08. *p* value for (log-hs-TnT)^2^: All-cause mortality, p = 0.02; Cardiovascular mortality, p = 0.007*ACEI* angiotensin converting enzyme inhibitor, *ARB* angiotensin II receptor blocker, *eGFR* estimated glomerular filtration rate (CKD-EPI equation), *hs*-*CRP* high-sensitivity C reactive protein, *hs*-*TnT* high-sensitivity troponin T, *LVEF* left ventricular ejection fraction, *NYHA* New York Heart Association, *NTproBNP* N-terminal pro-brain natriuretic peptide, *STfR* soluble transferrin receptor^a^Log-transformed and per 1 SD^b^Per 10 ng/mL Table 3C-statistics for risk of all-cause and cardiovascular death in diabetic patientsAll-cause deathCardiovascular deathAUC95% CIAUC95% CIClinical model0.7330.683--0.7830.6440.589--0.707 +NT-proBNP0.7510.702--0.8000.6660.606--0.624 +Hs-TnT0.7900.735--0.8440.6710.606--0.637 +ST20.7900.735--0.8460.6460.579--0.713 +Neprilysin0.7330.683--0.7830.6480.589--0.707 +Galectin-30.7800.724--0.8350.6500.583--0.716 +Cystatin-C0.7810.725--0.8360.6470.580--0.715 +Hs-CRP0.7690.710--0.8270.6390.571--0.707 +STfR0.7660.707--0.8240.6330.565--0.701 +Hs − TnT + ST20.8110.759--0.8630.6830.617--0.748 +Hs − TnT + ST2 + NT-proBNP0.8100.757--0.8630.6900.625--0.754 +Hs − TnT + ST2 + cystatin-C0.8120.759--0.864---- +Hs − TnT + ST2 + galectin-3----0.6990.635--0.763Clinical model: age, sex, New York Heart Association functional class, left ventricular ejection fraction, and estimated glomerular filtration rate (CKD-EPI equation); *hs*-*CRP* high-sensitivity C reactive protein, *hs*-*TnT* high-sensitivity troponin T, *NTproBNP* N-terminal pro-brain natriuretic peptide, *STfR* soluble transferrin receptor

Discussion {#Sec16}
==========

The present study was performed in a large cohort of ambulatory patients with HF and included a long-term follow-up. The three main findings were as follows. First, the levels of most of the biomarkers that we studied were higher in diabetic patients; however, when we adjusted for confounders, only NT-proBNP, hs-TnT, and sTfR were significantly higher in diabetic patients. Secondly, independent of the finding stated above, we did not find any differences between nondiabetic and diabetic patients for most of the biomarkers with respect to prognostic value for all-cause and cardiovascular mortality. Finally sST2 which was a significantly predictor for both all-cause and cardiovascular death in both diabetic and nondiabetic subjects was associated with an appreciably higher risk in the nondiabetic patients. This biomarker together with hs-TnT were the only markers that were independently associated with both all-cause and cardiovascular mortality in the diabetic patients of our cohort. Some of the biomarkers that we investigated have been shown in previous studies to be predictors of the incidence of cardiovascular events and prognosis in diabetic patients and some of them have also shown to help in distinguishing those individuals with a high risk of CV disease among diabetic subjects \[[@CR19]\]. In elderly patients with DM, NT-proBNP is a strong independent predictor of short-term cardiovascular mortality, including patients without preexisting cardiovascular disease \[[@CR20]\]. Also, in type 2 diabetic patients with microalbuminuria but without known coronary artery disease, NT-proBNP has been shown to be strongly associated with future CV events \[[@CR17]\]. Moreover, hs-TnT levels in diabetic subjects were recently described as the strongest predictor (in addition to sST2 and hs-CRP) of short-term outcome in patients with stable coronary artery disease \[[@CR21]\]. Also in type 2 diabetic patients, normal hs-TnT level has a high negative predictive value for future adverse CV events \[[@CR22]\]. In the present study there were no interactions between the majority of the biomarkers and DM with respect to prediction of risk of all-cause or cardiovascular death. However, ST2 significantly interacted with DM for all-cause and cardiovascular death being associated with a higher risk in nondiabetic compared to diabetic patients. Experimental and human studies have suggested relationships between ST2 and myocardial stretch, fibrosis, adverse cardiac remodelling, inflammation, impaired haemodynamics, and vascular disease \[[@CR23]\]. Indeed, in experimental studies ST2 appears to play a pivotal role in LV remodeling; this process comprises changes in cardiac structure, myocardial composition, myocyte deformation, and multiple biochemical and molecular alterations that impact heart function and reserve capacity \[[@CR24]\]. The currently available data are insufficient to allow us to determine conclusively whether the value of ST2 as a marker of cardiac remodelling is different in patients with and without diabetes. That is, patients with diabetes may be affected by other variables such as advanced glycation end products, inflammatory markers, or microvascular damage that may be involved in the remodelling process and thus could explain the difference in the prognostic value of ST2 concentrations between patients with and without DM. On the other hand, the source of ST2 is not well established; although it is known to be produced by both cardiac fibroblasts and cardiomyocytes in response to injury or stress, nonmyocardial production by endothelial cells has also been suggested \[[@CR25]\]. The multivariable Cox regression analysis showed that ST2 together with hs-TnT were the only biomarkers analysed in the present study that were independently associated with heart failure prognosis (all-cause and cardiovascular mortality) in diabetic patients. Moreover, the combination of two biomarkers (ST2 together with hs-TnT) increased the predictive value of HF prognosis compared to what is obtained when only one of them is determined.

Diabetes is widely recognized as a significant risk factor for the development of HF and is an independent risk factor for increased mortality among individuals with HF. Indeed, HF is one of the most common initial manifestation of cardiovascular disease in patients with T2D \[[@CR3]\]. Thus, it is of clinical interest to investigate whether the biomarkers used for assessing the prognosis of heart failure perform similarly in diabetic and non-diabetic subjects (both with regard to its serum concentrations and as to its prognostic value). To our knowledge there are no studies to date that have specifically addressed whether current predictive biomarkers used in the general population with heart failure are also useful in patients with diabetes. Our conclusion is that, in our cohort of HF patients, biomarkers used in the general population to predict the clinical course of heart failure are also useful in patients with diabetes. In these patients, among all the biomarkers analysed only hs-TnT and ST2 were independently associated with both all-cause and cardiovascular mortality. The use of a combination of biomarkers (multimarker strategy) in predicting the risk of death seems to be in diabetic patients as good as in the general population with HF \[[@CR10]\], improving discrimination, mainly when two biomarkers are combined.

Limitations {#Sec17}
-----------

A limitation of this study is that most of the diagnoses of DM were made from clinical records, treatment regimens, and, for some patients, blood chemistry data alone. However, most previous diabetes studies used this form of data acquisition. Indeed, patients were classified into nondiabetic and diabetic subgroups according to their baseline diagnosis and no data on new-onset diagnosis of DM during follow-up were considered. Additionally, we could not assess the impact of diabetes duration as a powerful contributing factor in these patients. Although our study participants were drawn from the general population attending an HF unit, the unit is located at a tertiary university hospital and the cohort patients were mainly male and of ischaemic aetiology. The great majority had been admitted to a hospital in the previous year or had depressed LVEF. Therefore, we cannot disregard the possibility of bias due to selection of patients who may not necessarily represent the general HF population.

Conclusions {#Sec18}
===========

DM has little impact on the predictive power of the HF biomarkers NT-proBNP, hs-TnT, galectin-3, hs-CRP, cystatin-C, sTfR, and neprilysin. Only ST2, which had predictive value in both diabetic and nondiabetic patients, was associated with a higher risk in nondiabetic patients.

DM

:   diabetes mellitus

HF

:   heart failure

hs-TnT

:   high-sensitivity troponin T

hs-CRP

:   high-sensitivity C reactive protein

sTfR

:   soluble transferrin receptor

LVEF

:   left ventricular ejection fraction

NYHA

:   New York Heart Association

NT-proBNP

:   N-terminal pro-brain natriuretic peptide
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